"HiCy" relieves MS symptoms
Update on Relapsing-Remitting MS: B-cell Depletion with Rituximab
IIn this article review, Dr. Bruce Cree comments on a recent clinical trial that explored the use of rituximab, a monoclonal antibody directed against CD20+ B lymphocytes, as therapy for patients with multiple sclerosis.
Source: Projects In Knowledge [more]
http://broadcaster.medpagetoday.com/t?r=2&c=2006&l=15&ctl=DB6C:961584531C0AE5126CFF4A85DF5E0100
MS Market is Estimated to Be Worth Almost US$8 Billion in 2008 ...
MarketWatch - USA
Orchestra Therapeutic's NeuroVax targets three proteins expressed on T-cell receptors whilst Opexa Therapeutics' Tovaxin uses attenuated autologous cells to ...
Woman living with MS urges education
Morehead News - Morehead,KY,USA
There are four types of MS: Relapsing-remitting multiple sclerosis, Primary-progressive multiple sclerosis (also called PPMS), Secondary-progressive ...
New Quality Assurance On The Way For Health And Social Care Information, UK
The MS Society has been chosen by the Department of Health from over 120 applications to participate in the testing phase of a new scheme to ensure good quality information across the health and social care sector.
Teva Initiates Phase III Study To Confirm Increased Efficacy Of ...
By Phil(Phil)
About Multiple Sclerosis Multiple Sclerosis (MS) be the intervening organize to of neurological disability in childlike adults. It is inexact that 400000 relations in the United States be wooden with this illness, ...
Symptoms and Management
Dr. Murray
Professor Emeritus of Medicine (Neurology)
View BIO
Q :
I was diagnosed with MS about 12 years ago and over time have noticed that my symptoms are much improved on the first day of my period. Is there any research into the impact of hormone level fluctuation on MS?
A :
The observation that symptoms of MS might improve on the first day of a menstrual period may again demonstrate the way the disease has very individual effects on each person. This is an interesting but unusual observation, as most women note no difference with their periods and those who do usually complain that their symptoms are worse in the days prior to a period.
As to hormonal research in MS, there has been a lot of study as some observations have been long noted - MS relapses are decreased during pregnancy, and increased in the three to six months post-partum; and as mentioned some women note worsening of symptoms before a period. Also, there has been interest in some estrogen compounds as potential therapy for MS, and there are some studies now underway. Hormonal connections and their feed- back mechanisms are very complex, so our understanding of the possibilities here for improvement and worsening are very incomplete.
In the course of investigations of MS characteristics we always find some people who seem to have differences or even opposite responses and these are not only interesting, but may be informative, so keeping a close record of these could be important.
9/2/2008 11:10:38 PM
More answers from Dr. Jock Murray
http://www.msanswers.ca/QuestionListByExpert.aspx?EID=32&L=2
More answers in the category: Symptoms and Management
http://www.msanswers.ca/QuestionList.aspx?CID=10&L=2
DISCLAIMER: Please be aware that this information does not necessarily represent the opinion of the MS Society of Canada, and is not intended as medical advice. For specific advice and opinion, always consult a physician.
© 2008 Multiple Sclerosis Society of Canada | www.mssociety.ca
http://www.mssociety.ca
http://www.msanswers.ca/QuestionView.aspx?L=2&QID=2181
Newsletter
September 2008
Connect with others whose lives are affected by MS, like songwriter Mark Gilligan.
The average onset of symptoms is between 30 and 35 years of age. Most people are diagnosed with MS between 20 and 50.
Society-funded Study Shows Evidence of Nerve Regeneration within MS Lesions
Research News
The Hunt Is On!
A recent study proved what many people with MS suspected: genes play a role in making people susceptible to the disease. Now the hunt for genetic MS triggers is expanding — and the Society is helping.
Read more >>
Getting Results
Much Music; More Money
MS activists in New Jersey have become impresarios, raising millions with an annual concert. This year Smokey Robinson headlined, but the real news was how many people with MS the program will support.
Read more >>
Moving Forward
Scolarship Program
This fall Laura Hermanns started college with a four-year Presidential Scholarship from the Society. She credits her father Walter, who lives with MS, as being a great influence. Read more about Laura and other Society scholars >>
Get Involved
2008-2009 Membership Drive
Help us reach our goal so we can help people with MS reach theirs. Your gift today will help us reach our goal — 1,500 new members online by midnight on September 10th. Make your 2008-2009 Member Drive gift today!
This communication is partially sponsored through the generous support of Biogen Idec, EMD Serono, Inc. and Pfizer, Inc.
National MS Society | View as Web page | Subscribe | Legal Notice/Privacy Policy | Unsubscribe
MS stops people from moving. The National MS Society exists to make sure it doesn’t.
We are a collective of passionate individuals, moving together to create a world free of MS.
JOIN THE MOVEMENT
Early and ongoing treatment with an FDA-approved therapy can make a difference for people with multiple sclerosis. Learn about your options by talking to your health care professional and contacting the National MS Society at http://www.nationalmssociety.org/ or 1-800-344-4867.
National Multiple Sclerosis Society | 733 Third Avenue | New York, NY | 10017
This message was sent to fooledbyasmile@mountaincable.net.
To ensure that you continue to receive our emails, please add us to your address book.
Study: Direct-to-Consumer Ads May Be Waste of Cash
Pharma may be throwing away billions of dollars on ad campaigns in the U.S., according to a probe into the effectiveness of media blitzes to promote a drug directly with the public. "People tend to think that if direct-to-consumer advertising wasn't effective, Pharma wouldn't be doing it," said the study's leader. "But as it turns out, decisions to market directly to consumers are based on scant data." To overcome that, the study's leader went to Canada to study the English-speaking population, who are exposed to DTC advertising from the U.S. versus the French, who are not.
http://www.therapeuticsdaily.com/news/article.cfm?contentValue=1831148&contentType=sentryarticle&channelID=33
Study: Direct-to-Consumer Ads May Be Waste of Cash
AFP World News / English - Sep. 02, 2008
PARIS, Sept 2, 2008 (AFP) -
Big Pharma may be throwing away billions of dollars on ad campaigns in the United States, according to a probe into the effectiveness of media blitzes to promote a drug directly with the public.
In 1997, the United States lifted a ban on prescription-drug ads that are pitched directly at the public rather than at doctors or other health professionals.
The change prompted pharmaceutical companies to invest heavily in retail advertising, and annual spending in this sector now averages more than five billion dollars (four billion euros).
Advocates of direct-to-public drug advertising say it raises awareness and encourages the treatment of neglected conditions.
Critics counter that it artificially drives up demand for expensive novel drugs that have not been tested over the long haul.
Both sides, though, have assumed that the marketing technique works -- but the new study suggests they have got it flat wrong.
"People tend to think that if direct-to-consumer advertising wasn't effective, Pharma wouldn't be doing it," said Harvard Medical School professor Stephen Soumerai, who led the investigation.
"But as it turns out, decisions to market directly to consumers are based on scant data."
Even when sales increase, it has been nearly impossible to isolate the impact of targeting consumers from, say, marketing campaigns directed at doctors and health professionals.
Ideally, one would want to compare two otherwise identical populations before and after one of them is exposed to direct-to-consumer ads for certain drugs in order to measure the difference.
In the United States that is not possible, so Soumerai came up with a clever idea: Canada.
Direct-to-consumer ads for prescription drugs are illegal north of the US border, but English-speaking Canadians are still massively exposed to pharma advertising on American television and radio, and in US magazines.
Their French-speaking neighbours in the Canadian province of Quebec, however, are not, which provided the investigators with a useful group for making a comparison.
The study focused on three drugs: Enbrel, for arthritis; Nasonex, for allergies; and Zelnorm, for irritable bowel syndrome.
All three had been on the market in both countries for at least one year before the direct-to-consumer campaigns began in the United States.
The question was simple: once the ads kicked in, did sales increase more quickly in English-speaking Canada than in Quebec?
Based on data from a registry of 2,700 pharmacies, the answer for the first two drugs was a clear "no", while for the third drug, sales initially leapt in the Canadian anglophone market but then fell back.
The study was published online on Tuesday by the British Medical Journal (BMJ).
Sales of Zelnorm initially jumped 40 percent, but within a couple of years prescription rates in both groups were the same again.
Given that Zelnorm was the only drug available for that syndrome, it might have sold as well without the direct-to-consumer ads.
Soumerai thinks the ads failed because the process of buying prescription drugs is not as easy or spontaneous as buying over-the-counter medication such as aspirin.
A person has to see an ad, get motivated, contact their doctor, show up for an appointment, communicate both the condition and the drug, convince the doctor to prescribe it, and then actually fill the prescription, which is also likely to carry an out-of-pocket cost, he explained.
The United States is one of only two countries in the world -- along with New Zealand -- where direct-to-consumer ads for prescription medication is legal.
In March 2007, Zelnorm was pulled from the market due to concerns about increased risk of heart attack and stroke.
mh/ri/gk
http://www.therapeuticsdaily.com/news/article.cfm?contentValue=1831148&contentType=sentryarticle&channelID=33
MS Market is Estimated to Be Worth Almost US$8 Billion in 2008 ...
StreetInsider.com (subscription) - Birmingham,MI,USA
... GLOSSARY - MS REFERENCES - ACRONYMNS Key Products Analysed and Forecast: - BG-12 - Biogen Idec - Campath - Bayer - Fingolimod - Novartis - Lacquinimod ...
http://www.streetinsider.com/Press+Releases/MS+Market+is+Estimated+to+Be+Worth+Almost+US$8+Billion+in+2008,+with+a+Growth+Rate+of+10.6%25+Year-on-Year/3954366.html
MS Market is Estimated to Be Worth Almost US$8 Billion in 2008, with a Growth Rate of 10.6% Year-on-Year
Last update: 10:10 a.m. EDT Sept. 2, 2008
| |
DUBLIN, Ireland, Sep 02, 2008 (BUSINESS WIRE) -- Research and Markets http://www.researchandmarkets.com/research/f0d42d/cns_drug_discoveri) has announced the addition of the "CNS Drug Discoveries: Multiple Sclerosis Chapter" report to their offering.
This chapter of CNS Drug Discoveries focuses on the multiple sclerosis market.
With the launch of up to 12 new disease-modifying agents, three vaccines and one novel drug designed to treat the symptoms of multiple sclerosis (MS) and improve quality of life, the MS market is in an exciting phase of evolution.
The MS market is estimated to be worth almost US$8 billion in 2008, with a growth rate of 10.6% year-on-year. It is the fifth largest segment of the CNS markets considered in this report and has attracted considerable R&D investment from the big pharmaceutical companies, biotechnology companies and specialty pharma.
Over the next six years a number of oral agents are expected to be launched that could drastically change the way in which MS patients are treated. These include: Novartis' fingolimod, Teva's laquinimod, Merck KGaA's Mylinax (cladribine), sanofi-aventis' teriflunomide and Biogen Idec's BG-12 in Phase III development, and GSK/Mitsubishi Tanabe Pharma's firategrast, MediciNova's ibudilast and Biogen/UCB's CDP323 in Phase II development.
Three companies have taken on the ambitious task of developing vaccines to treat MS and each has adopted a unique approach to addressing the underlying causes of the disease. Orchestra Therapeutic's NeuroVax targets three proteins expressed on T-cell receptors whilst Opexa Therapeutics' Tovaxin uses attenuated autologous cells to stimulant an immune response. Bayhill Therapeutics is developing BHT-3009, a tolerising DNA vaccine. All vaccines are in Phase II development and could reach market by 2012.
Key MS questions answered:
-- What is the estimated global population for MS in 2014 and what % will be diagnosed and treated?
-- Which off-patent MS treatments are resistant to generic competition?
-- Will Biogen Idec, Teva and Merck KGaA be able to defend their leading positions in 5 years time?
-- There are 7 late-phase pipeline products which target the underlying cause of MS -- what are their strengths and weaknesses?
Key Topics Covered:
- EXECUTIVE SUMMARY
- THE FACTS
- PATIENT STATISTICS
- PATIENT MODEL
- DRUG GROWTH DRIVERS
- DRUG GROWTH RISKS/DAMPENERS
- THE MS MARKET
- CURRENT MS TREATMENTS
- GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2007A-2014E
- ANALYSIS OF PHASE III DRUGS
- GLOBAL SALES FORECASTS OF PHASE III MS DRUGS 2009E-2014E
- ANALYSIS OF PHASE II DRUGS
- GLOBAL SALES FORECASTS OF PHASE II MS DRUGS 2011E - 2014E
- COMPETITOR RATIO ANALYSIS
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- COMPETITOR RATIO ANALYSIS - COMPANIES
- WINNERS & LOSERS
- DISCONTINUATION OF DRUGS
- MS GLOSSARY
- MS REFERENCES
- ACRONYMNS
Key Products Analysed and Forecast:
- BG-12 - Biogen Idec
- Campath - Bayer
- Fingolimod - Novartis
- Lacquinimod - Teva
- MBP 8298 - BioMS/Lilly
- Mylinax - Merck KGaA
- Teriflunomide - sanofi-aventis
- Neurelan - Elan/Acorda
For more information visit http://www.researchandmarkets.com/research/f0d42d/cns_drug_discoveri
Source: Espicom Business Intelligence Ltd
SOURCE: Research and Markets Ltd.
Research and MarketsCopyright Business Wire 2008
Laura Wood, Senior Manager
press@researchandmarkets.com
Fax (USA): 646-607-1907
Fax (International): +353-1-481-1716
Jobs for old brain's new neurons
A close look at neurogenesis in two regions of the adult brain
By Andrea Gawrylewski
Obama: Yes to stem cells, funding
The Democratic presidential nominee's responses to a science policy survey outlines support for science
By Bob Grant
Stem cell alchemy
Researchers flip fully-differentiated cells in vivo into another type of cell without first reprogramming them to a pluripotent state By Andrea Gawrylewski
Scientists report converting cells to new type
directly:
Research described as a major advance sidesteps
previous complications with the production of stem
cells for medical treatment.
http://www.world-science.net/othernews/080827_cells
Cancer cells may "prepare" earlier than thought:
New studies on mice suggest disturbing conclusions
but also could inspire new therapeutic strategies,
researchers say.
http://www.world-science.net/othernews/080829_cancer
Location, Location, Location Important For Genes, Too
Cells become cancerous mainly because they lose control of their growth. To better understand how this happens, a new study at Ohio State University's Comprehensive Cancer Center looks at four genes that help regulate cell growth in embryos and that contribute to cancer in adults.
Natural ways to lower blood pressure
By Joe Graedon, Teresa Graedon
Also: Atkins diet and good HDL levels >>
http://link.latimes.com/r/LV1G9U/A4WOQ/NUJXHK/GSHK/I2XA5/D5/h
Natural ways to lower blood pressure
HeartBeet is a "beetroot" juice brand sold in Britain. We have not seen it in the U.S.
A study published in Hypertension (March) showed that two cups of beet juice daily lowered blood pressure by about 10 points, equivalent to the effect of many blood-pressure medicines.
Beets and certain other vegetables are high in nitrates. Eating a diet rich in natural nitrates seems to increase nitric oxide, a compound made in the body that relaxes blood vessels and lowers blood pressure.
Your husband should not stop taking his medication, but he might consider adopting a vegetable-rich DASH diet and including pomegranates, Concord grapes or a little dark chocolate in his diet as well. Weight loss and relaxation exercises can also contribute to natural blood-pressure control.
----------------------------------------------------------------------------------------
I heard that eating an Atkins diet could raise good HDL levels. Surely that is not true! Presumably all that saturated fat raises bad cholesterol even more.
In a recent study (New England Journal of Medicine, July 17), a low-carb Atkins-style diet resulted in higher good HDL cholesterol and lower triglycerides than a standard low-fat diet. Bad LDL cholesterol was not significantly different.
Reach Joe Graedon, a pharmacologist, and Teresa Graedon, an expert in medical anthropology and nutrition, at www.peoplespharmacy.com or in care of this newspaper.
Computed Tomography Provides Anatomy - We Need Ischemia!
Cardiac computed tomography has revolutionized cardiac imaging in recent years by providing exquisitely detailed cardiac anatomy, including, but not limited to, coronary anatomy. Non-invasive coronary angiography by computed tomography (CTA) is performed in ever increasing numbers, over 150 000 per year in the United States.
Fertility News
Discovery Of Master Switch In The Brain That Regulates Appetite And Reproduction
Body weight and fertility have long known to be related to each other - women who are too thin, for example, can have trouble becoming pregnant. Now, a master switch has been found in the brain of mice that controls both, and researchers at the Salk Institute for Biological Studies say it may work the same way in humans.
MS Market is Estimated to Be Worth Almost US$8 Billion in 2008, with a Growth Rate of 10.6% Year-on-Year
MS Market is Estimated to Be Worth Almost US$8 Billion in 2008, with a Growth Rate of 10.6% Year-on-Year
Last update: 10:10 a.m. EDT Sept. 2, 2008
DUBLIN, Ireland, Sep 02, 2008 (BUSINESS WIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/f0d42d/cns_drug_discoveri) has announced the addition of the "CNS Drug Discoveries: Multiple Sclerosis Chapter" report to their offering.
This chapter of CNS Drug Discoveries focuses on the multiple sclerosis market.
With the launch of up to 12 new disease-modifying agents, three vaccines and one novel drug designed to treat the symptoms of multiple sclerosis (MS) and improve quality of life, the MS market is in an exciting phase of evolution.
The MS market is estimated to be worth almost US$8 billion in 2008, with a growth rate of 10.6% year-on-year. It is the fifth largest segment of the CNS markets considered in this report and has attracted considerable R&D investment from the big pharmaceutical companies, biotechnology companies and specialty pharma.
Over the next six years a number of oral agents are expected to be launched that could drastically change the way in which MS patients are treated. These include: Novartis' fingolimod, Teva's laquinimod, Merck KGaA's Mylinax (cladribine), sanofi-aventis' teriflunomide and Biogen Idec's BG-12 in Phase III development, and GSK/Mitsubishi Tanabe Pharma's firategrast, MediciNova's ibudilast and Biogen/UCB's CDP323 in Phase II development.
Three companies have taken on the ambitious task of developing vaccines to treat MS and each has adopted a unique approach to addressing the underlying causes of the disease. Orchestra Therapeutic's NeuroVax targets three proteins expressed on T-cell receptors whilst Opexa Therapeutics' Tovaxin uses attenuated autologous cells to stimulant an immune response. Bayhill Therapeutics is developing BHT-3009, a tolerising DNA vaccine. All vaccines are in Phase II development and could reach market by 2012.
Key MS questions answered:
-- What is the estimated global population for MS in 2014 and what % will be diagnosed and treated?
-- Which off-patent MS treatments are resistant to generic competition?
-- Will Biogen Idec, Teva and Merck KGaA be able to defend their leading positions in 5 years time?
-- There are 7 late-phase pipeline products which target the underlying cause of MS -- what are their strengths and weaknesses?
Key Topics Covered:
- EXECUTIVE SUMMARY
- THE FACTS
- PATIENT STATISTICS
- PATIENT MODEL
- DRUG GROWTH DRIVERS
- DRUG GROWTH RISKS/DAMPENERS
- THE MS MARKET
- CURRENT MS TREATMENTS
- GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2007A-2014E
- ANALYSIS OF PHASE III DRUGS
- GLOBAL SALES FORECASTS OF PHASE III MS DRUGS 2009E-2014E
- ANALYSIS OF PHASE II DRUGS
- GLOBAL SALES FORECASTS OF PHASE II MS DRUGS 2011E - 2014E
- COMPETITOR RATIO ANALYSIS
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- COMPETITOR RATIO ANALYSIS - COMPANIES
- WINNERS & LOSERS
- DISCONTINUATION OF DRUGS
- MS GLOSSARY
- MS REFERENCES
- ACRONYMNS
Key Products Analysed and Forecast:
- BG-12 - Biogen Idec
- Campath - Bayer
- Fingolimod - Novartis
- Lacquinimod - Teva
- MBP 8298 - BioMS/Lilly
- Mylinax - Merck KGaA
- Teriflunomide - sanofi-aventis
- Neurelan - Elan/Acorda
For more information visit http://www.researchandmarkets.com/research/f0d42d/cns_drug_discoveri
Source: Espicom Business Intelligence Ltd
SOURCE: Research and Markets Ltd.
Research and MarketsCopyright Business Wire 2008
Laura Wood, Senior Manager
press@researchandmarkets.com
Fax (USA): 646-607-1907
Fax (International): +353-1-481-1716
posted by Bill at 1:45 AM
0 Comments:
Post a Comment
<< Home